PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26713361-0	2016	Evodiamine selectively targets cancer stem-like cells through the p53-p21-Rb pathway.	evodiamine	0-10	H3 histone pseudogene 16	Homo sapiens	70-73	
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	evodiamine	115-125	H3 histone pseudogene 16	Homo sapiens	340-343	
30396956-8	2018	In transforming growth factor-beta-treated cells, evodiamine attenuated variations in morphology, growth and migration, and increased p21 and p53 protein levels, and decreased beta-catenin, N-cadherin, vimentin, phospho-AKT, matrix metalloproteinase-2 and matrix metalloproteinase-9 protein levels.	evodiamine	50-60	H3 histone pseudogene 16	Homo sapiens	134-137	
26713361-7	2016	Surprisingly, evodiamine selectively activated p53 and p21 and decreased inactive Rb, the master molecules in G1/S checkpoint.	evodiamine	14-24	H3 histone pseudogene 16	Homo sapiens	55-58	
15821341-2	2005	After treatment with evodiamine for the indicated time periods, anti-apoptotic protein SIRT1 expression was decreased; p53 expression and its phosphorylation were both enhanced, whereas transient induction of downstream p21 was not enough to promote cell cycle arrest.	evodiamine	21-31	H3 histone pseudogene 16	Homo sapiens	220-223